NASDAQ:BCYC
Bicycle Therapeutics PLC
Bicycle Therapeutics PLC's revenue grew 105.8% in fiscal 2025 to $72.6M while operating margin rose to −340.4%. Free cash flow was −$252.0M, −347.2% of revenue, and the diluted share count rose 19.0%.Summary generated from Bicycle Therapeutics PLC's SEC filings. Latest annual report filed Mar 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$72.6M
Revenue growth+105.8%
Revenue, 5-yr CAGR+47.5%
Gross marginn/a
Operating margin−340.4%
Net margin−301.7%
ROICn/a
Return on equity−31.2%
Debt / equityn/a
Free cash flow−$252.0M
FCF margin−347.2%
Share count change+19.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 12 | 14 | 27 | 35 | 73 |
| Operating income | −66 | −117 | −190 | −210 | −247 |
| Net income | −67 | −113 | −181 | −169 | −219 |
| Free cash flow | −17 | −105 | −64 | −166 | −252 |
Recent filings
- 4Insider transaction report
Oct 6, 2026 - 4Insider transaction report
Oct 6, 2026 - 8-KDirector or officer change
Aug 20, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KResults of a shareholder vote
Jun 18, 2026 - 8-KOther events
May 21, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 30, 2026